×

GW Pharma has investors on a high

11:44 AM ET Mon, 14 March 2016

GW Pharma's phase 3 study on its cannabinoid Epidiolex shows positive results for epilepsy, sending shares of the company higher, reports CNBC's Meg Tirrell.